FDA NEWSNews FDA Approves Isembyld (Apitegromab-mstn), First Muscle-Targeted Therapy for Spinal Muscular Atrophy
Latest NewsNewsWe’re Heading to ESMO Congress 2025 in Berlin We’re Heading to ESMO Congress 2025 in Berlin
FDA NEWSNews FDA Approves Qfitlia (Fitusiran) for Hemophilia A or B, with or without Factor Inhibitors
